In two different preclinical tumor models (T3 MCA-induced sarcoma and SMA560 glioma), anti-tumor activity of SNV-neoantigen specific CD8 T cells could only be observed with MHCII neoantigen co-expression by tumor cells [167,168]. Here, CD8A is linked to sarcoma.